HalioDx is Now Part of Veracyte! Learn About HalioDx Read the Press Release
Search Tool Menu
HalioDx is Now Part of Veracyte! Learn About HalioDx Read the Press Release
Close Button
Reducing Unnecessary Surgeries and Informing Treatment Decisions in in cancer and other diseases

Our product pipeline reflects our strategy of answering clinical questions in our indications across the clinical care continuum. We develop new products both organically using our RNA whole-transcriptome sequencing and machine learning platform and through corporate acquisitions. In December 2019, we acquired the nCounter® diagnostics platform, positioning us to make our genomic tests available to physicians and patients worldwide through a distributed platform in which the tests are performed in local laboratories. This transaction also enables us to expand our genomic test offerings into new oncology indications (breast cancer and lymphoma). We believe the global market opportunity for our products is over $40 billion annually. 

Nasal Swab Test for Early Lung Cancer DetectionIn October 2019, we announced preliminary clinical data showing that our noninvasive nasal swab test – the first of its kind – may enable early lung cancer detection and diagnosis so that more lives can be saved. The preliminary findings show that our novel genomic test has the potential to accurately classify lung cancer risk in patients with lung nodules so that these patients may obtain the prompt diagnosis and potential treatment they need or may be monitored noninvasively. The in-development test uses “field of injury” technology to determine the likelihood that a lung nodule is cancerous by measuring gene expression patterns in cells collected from the nose. Veracyte plans to introduce the nasal swab test commercially in the fourth quarter of 2021.

LymphMark™ Lymphoma Subtyping TestThe LymphMark test is in development on the nCounter platform. The test uses the gene expression profile of cells found in Diffuse Large B-cell Lymphoma (DLBCL) tissue for the classification of Cell-of-Origin subtype of DLBCL into Activated B-Cell or Germinal Center B-Cell or an unclassified result. DLBCL is a heterogeneous group of cancers that represents the most common form of Non-Hodgkin Lymphoma. According to the National Cancer Institute, there were approximately 70,000 new cases of Non-Hodgkin Lymphoma in the United States in 2015.

Pipeline Chart